Vedolizumab Proves Its Worth in Treating Chronic Pouchitis
(MedPage Today) -- Vedolizumab (Entyvio) was more effective at inducing remission in patients with chronic pouchitis after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis compared with placebo, a randomized phase IV trial showed.
Among... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - March 29, 2023 Category: Gastroenterology Source Type: news
Peninsula cell therapy company lands big deal with Regeneron
While most cell therapy companies target cancer, Sonoma Bio is hitting autoimmune and inflammatory diseases, including rheumatoid arthritis, ulcerative colitis and more. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 28, 2023 Category: American Health Authors: Ron Leuty Source Type: news
Ustekinumab Effectiveness and Safety in Ulcerative Colitis Ustekinumab Effectiveness and Safety in Ulcerative Colitis
Does the effectiveness and safety of ustekinumab seen in clinical trials translate to real-world clinical outcomes?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 23, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Episode 3: Pregnancy, Fertility, Ulcerative Colitis: Facts vs Fiction Episode 3: Pregnancy, Fertility, Ulcerative Colitis: Facts vs Fiction
Join Drs Sunanda Kane and Uma Mahadevan as they set out to separate fact from fiction when treating patients with ulcerative colitis before, during, and after pregnancy.Medscape (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - March 21, 2023 Category: Surgery Tags: Gastroenterology InDiscussion Source Type: news
Comparing Tofacitinib and Vedolizumab in Ulcerative Colitis Comparing Tofacitinib and Vedolizumab in Ulcerative Colitis
Which of these two drugs is the most effective option for ulcerative colitis patients who previously failed anti-TNF treatment?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 21, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Clinical Guideline Developed for Use of Biomarkers in Ulcerative Colitis
FRIDAY, March 17, 2023 -- In a clinical practice guideline issued by the American Gastroenterological Association and published in the March issue of Gastroenterology, recommendations are presented for the role of biomarkers in the management of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 17, 2023 Category: Pharmaceuticals Source Type: news
TREMFYA ® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis
SPRING HOUSE, PENNSYLVANIA, March 17, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data, showing that initiation of TREMFYA® (guselkumab) was associated with greater treatment persistencea compared to secukinumab or ixekizumab in bio-naïve and bio-experienced patientsb living with moderate to severe plaque psoriasis (PsO), based on pairwise analysesc of real-world data.[1],[2] Additionally, in a post-hoc analysis of Phase 3 VOYAGE 2 clinical trial results, TREMFYA demonstrated durable clinical efficacy, itch relief and quality-of-life improvements in patients living with scal...
Source: Johnson and Johnson - March 17, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Upadacitinib Shows Positive Endoscopic Outcomes in Crohn's Disease Upadacitinib Shows Positive Endoscopic Outcomes in Crohn's Disease
Already FDA approved for ulcerative colitis, upadacitinib improves endoscopic response versus placebo in people with Crohn ' s disease, research shows.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 16, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Ulcerative Colitis Cases Projected to Top 2 Million by 2031 Ulcerative Colitis Cases Projected to Top 2 Million by 2031
Diagnosed prevalent cases of ulcerative colitis in eight countries will top 2 million in 2031, with the United States having the most cases, according to newly released projections.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 16, 2023 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
AI Helps Predict Ulcerative Colitis Remission/Activity, Flare-ups AI Helps Predict Ulcerative Colitis Remission/Activity, Flare-ups
An AI tool can distinguish histological remission from activity in biopsies of UC and predict flare-ups -- and could have a role in both clinical trials and routine practice.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 14, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
AI Model Can Help Identify Ulcerative Colitis Remission, Activity
TUESDAY, March 14, 2023 -- An artificial intelligence (AI) model can distinguish histological remission from activity in biopsies of ulcerative colitis (UC) and can predict flare-ups, according to a study published online March 3 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 14, 2023 Category: Pharmaceuticals Source Type: news
Wake Forest Baptist patient ’s Post-it Note messages spread hope
Rebecca Barker is a 29-year-old patient who has been in and out of Atrium Health Wake Forest Baptist Medical Center for more than four years. She has ulcerative colitis, a condition affecting the digestive tract.
The disease has become very complicated, Barker said. “I’ve had close to 30 surgeries in the past 10 years.”
During Barker’s latest stay at Wake Forest Baptist, she started waving to patients and teammates she saw outside her window across the Comprehensive Cancer Center. She… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 14, 2023 Category: American Health Authors: Atrium Health Wake Forest Baptist Source Type: news
Nearly 1 in 3 Patients With IBD Affected by Skin Lesions Nearly 1 in 3 Patients With IBD Affected by Skin Lesions
No significant difference was found in skin lesion prevalence between patients with ulcerative colitis and Crohn ' s disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 9, 2023 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
IL-6 Inhibitor for UC Shows Some Promise in Mid-Stage Trial
(MedPage Today) -- Induction therapy with a novel interleukin 6 (IL-6) inhibitor for active ulcerative colitis yielded significantly higher rates of clinical response, remission, and mucosal healing than placebo, findings from a phase II study... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - March 7, 2023 Category: Gastroenterology Source Type: news
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
